Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This course focus is on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing and troubleshooting theranostic delivery. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 will be discussed.
The course includes didactic presentation from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer sessions to discuss practice implementation in various clinical settings (i.e. academic hospital vs community practice, nuclear medicine vs radiation oncology).
The purpose of the course is to increase physician, physicist, billing and administration understanding on how to effectively and safely develop a radiopharmaceutical program at their respective institutions.
This activity is available from April 26, 2023, through 11:59 p.m. Eastern time on April 25, 2026.
This activity was originally recorded at ASTRO’s 2022 Annual Meeting, October 23-27.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation physicists, radiation therapists, medical oncologists and other specialists.
Upon completion of this activity, participants should be able to:
- Evaluate radiation treatment options for patient use such as RPTs.
- Safely and effectively administer the new and growing list of active radiopharmaceuticals.
- Actively establish and develop RPT programs for patient care.
- Ana P. Kiess, MD, PhD, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore MD
- Hyun Kim, MD, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, St. Louis, MO
- Annick D. Van den Abbeele MD, Dana-Farber Cancer Institute, has an investment interest in Yunu, Inc.
- Stephen Graves PhD, University of Iowa, and receives compensation from CDE Dosimetry Inc., RayzeBio, MIM Software Inc., Voximetry.
- Zachary Scott Morris MD, PhD, Associate Professor at University of Wisconsin School of Medicine and Pub and has nothing to disclose.
- Richard Glenn Stock MD, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, and has nothing to disclose.
- Ana P. Kiess MD, PhD, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore MD, and receives compensation from Bayer, Merck, Novartis, POINT Biopharma.
- Jeff Michael Michalski MD, MBA, FASTRO, and has nothing to disclose.
- Jacqueline E Zoberi PhD, Medical Physicist at Washington University School of Medicine, Department of Radiation Oncology, and has nothing to disclose.
- Amir Iravani MD, Washington University School of Medicine, Department of Radiology, Division of Nuclear Medicine, and has nothing to disclose.
- Nichole Millward Maughan PhD, MS, Assistant Professor at Washington University School of Medicine, and has nothing to disclose.
- Hyun Kim MD, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, St. Louis MO, and receives compensation from Hanbeam, Varian, ViewRay.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 4.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 4.50 Certificate of AttendanceThis activity was designated for 4.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.